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ABSTRACT
The HOX genes encode a family of transcription factors that have key roles in 
both development and malignancy. Disrupting the interaction between HOX proteins 
and their binding partner, PBX, has been shown to cause apoptotic cell death in a 
range of solid tumors. However, despite HOX proteins playing a particularly significant 
role in acute myeloid leukemia (AML), the relationship between HOX gene expression 
and patient survival has not been evaluated (with the exception of HOXA9), and the 
mechanism by which HOX/PBX inhibition induces cell death in this malignancy is not 
well understood. In this study, we show that the expression of HOXA5, HOXB2, HOXB4, 
HOXB9, and HOXC9, but not HOXA9, in primary AML samples is significantly related to 
survival. Furthermore, the previously described inhibitor of HOX/PBX dimerization, 
HXR9, is cytotoxic to both AML-derived cell lines and primary AML cells from patients. 
The mechanism of cell death is not dependent on apoptosis but instead involves 
a regulated form of necrosis referred to as necroptosis. HXR9-induced necroptosis 
is enhanced by inhibitors of protein kinase C (PKC) signaling, and HXR9 combined 
with the PKC inhibitor Ro31 causes a significantly greater reduction in tumor growth 
compared to either reagent alone.
INTRODUCTION
The molecular mechanisms underlying the 
pathogenesis of acute myeloid leukemia (AML) have 
been extensively studied, and are known to involve 
members of the HOX family of transcription factors, 
both as partners in chimeric fusion proteins, and also in 
their wild type form [1]. Whilst these roles are reflected 
in the relationship between the expression of individual 
HOX genes and clinicopathological factors such as 
disease subtype and patient survival [2], the role of HOX 
proteins in the survival of AML cells has proved difficult 
to assess as many have redundant functions, which 
makes a conventional knock down experiment difficult to 
interpret. For example, knocking down the expression of 
either HOXA6 or HOXA9 alone has little effect on AML 
cells, but their double knock-down induces cell death 
and also increases their sensitivity to cytarabine [3]. An 
alternative strategy to targeting HOX proteins is to inhibit 
their interaction with the PBX co-factor, which can be 
achieved using a short, cell-penetrating peptide (HXR9) 
that mimics the conserved hexapeptide in HOX proteins 
responsible for PBX binding [4]. HXR9 has been shown to 
induce apoptosis in a range of solid cancers, both in vitro 
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and in vivo, including those of the lung [5], breast [6] and 
prostate [7], and melanoma [8]. It has also been shown to 
be cytotoxic for malignant B cells [9], and a number of 
AML cell lines [10]. However, the mechanism of HXR9 
induced-cell death is not well understood in hematological 
malignancies. In this study we evaluated the relationship 
between HOX gene expression and overall survival, and 
the mechanism by which HXR9 causes cell death in AML. 
Our findings indicate that HXR9 induces necroptosis, 
rather than apoptosis, and that its cytotoxicity can be 
greatly enhanced by inhibition of protein kinase C (PKC).
RESULTS
Despite the public availability of large datasets 
relating HOX gene expression to survival in AML, 
relatively little has been reported on the relationship 
between the expression of individual HOX genes and 
survival. We therefore analyzed the relationship between 
survival and expression of HOX genes that encode proteins 
capable of binding to the HXR9 target, PBX, amongst a 
cohort of 269 patients from the Gene Expression Omnibus 
(GEO) database [11]. This revealed that a number of HOX 
genes were significantly related to survival in AML, 
including HOXA5 (p = 0.03), HOXB2 (p = 0.002), HOXB4 
(p = 0.037), HOXB9 (p = 0.001), and HOXC9 (p = 0.007) 
(Figure 1), whilst HOXA4 (p = 0.067) and HOXA9 (p 
= 0.06) showed borderline significance. In contrast, the 
expression of a number of other HOX genes including 
HOXA1 (p = 0.242), HOXA2 (p = 0.595), HOXA3 (p = 
0.407), HOXA7 (p = 0.529), HOXB3 (p = 0.783), HOXB5 
(p = 0.979), HOXB6 (p = 0.246), HOXB7 (p = 0.996), 
HOXB8 (p = 0.74), and HOXC6 (p = 0.876) were not 
related to patient survival (data not shown).
In order to evaluate the molecular mechanisms 
underlying the cytotoxicity of HXR9 in AML cells, we 
determined the sensitivity of a number of AML-derived 
cell lines and primary AML cells. Three of the cell lines 
were derived from primary AML (KG1, HEL 92.1.7, 
and HL-60) and 2 from secondary AML (KU812F, and 
K562). The IC50s of cell killing by HXR9, as determined 
using an LDH assay, were 4.5, 6.1, 16.9, 9.1, and 10.4 
µM, respectively (Figure 2A). None of these cell lines 
were sensitive to CXR9, an inactive variant of HXR9 that 
differs from it by only a single amino acid [7]. In order to 
Figure 1: Association of expression of HOX genes in combination with AML patient survival data. Kaplan-Meier plots of 
the cumulative proportion of patients surviving in the AML dataset (n = 269) from the Gene Expression Omnibus database GSE23312 in 
patients with a low level and a high level of expression of each specified HOX gene.
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test the effect of HXR9 on primary AML cells we isolated 
cells from the peripheral blood of AML patients and used 
a proliferation assay to evaluate the response to HOX/
PBX inhibition. This revealed that HXR9 can significantly 
reduce the proliferation of primary AML cells at a 
concentration < 1 µM (Figure 2B), which is considerably 
lower than for other primary cancer cells isolated from 
solid malignancies [8].
We investigated whether these cells underwent 
apoptosis after HXR9 treatment. Although changes in the 
plasma membrane consistent with apoptosis were apparent 
in all of these cell lines (Figure 3), which concurs with 
previous findings [10], this is not in itself an absolute 
indication that cells have undergone apoptosis, as these 
membrane changes can also occur during necrosis [12]. 
Indeed, further studies with the K562 and HL-60 cell lines 
revealed no evidence of other, more definitive changes 
associated with apoptosis including caspase-3 activation 
(Figure 4A) or nuclear fragmentation (Figure 4B). We also 
measured the expression of a number of genes involved 
in apoptosis using qRT-PCR (Figure 4C). This analysis 
revealed that HXR9 did not cause transcriptional changes 
in the initiator caspase-9 or its partner Apaf1 that together 
form an apoptosome complex with cytochrome C (cyt C) 
[13], nor in the executioner caspases-3, -6 and -7, which 
are key mediators of apoptosis [14], nor the pro-apoptotic 
members of the Bcl-2 family including Bad, Bax, Bak1 and 
Bid, nor the anti-apoptotic member Bcl-2, which mediate 
mitochondrial cell death [15]. In addition, neither the 
transcription of PARP1 nor XIAP was affected by HXR9 
Figure 2: A. IC50 survival curves for AML-derived cell lines treated with HXR9 or CXR9. B. Proliferation of primary AML cells treated 
with varying concentrations of HXR9 or CXR9. Each value is the mean of 3 independent repeats, error bars show the SEM. 
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treatment. Furthermore, cell death was not dependent on 
ATP (Figure 4D), and could not be reversed by the pan-
caspase inhibitor z-VAD-FMK (Figure 4E). We therefore 
explored the possibility of necrotic cell death. K562 cells 
could be rescued from HXR9-mediated cell killing using 
CsA (Figure 4F), an inhibitor of mitochondrial necrosis 
that targets the CypD protein, although only a limited 
rescue was achieved in HL-60 cells (Figure 4G) [16]. 
However, inhibition of the RIP1 kinase using its inhibitor 
Nec-1 [17] resulted in a significant rescue of K562 and 
HL-60 cells from HXR9-mediated cytotoxicity (Figure 
5A). RIP1 is a central component of the necroptosis 
pathway [18], suggesting that this might play a key role 
in HXR9-induced cell death. We also explored further 
molecular pathways that might influence necroptosis. 
Inhibition of signaling through p38 (Figure 5B) and MEK/
ERK (Figure 5C) had no effect on HXR9 cytotoxicity, nor 
did the inhibition of the p53 tumor suppressor protein 
(Figure 5D), although HXR9 treatment of both K562 and 
HL-60 cells resulted in a significant increase in expression 
of the p21 tumor suppressor gene at both the RNA (Figure 
5E) and protein (Figure 5F) level. Furthermore, inhibition 
of PKC also significantly sensitized cells to HXR9 (Figure 
6). 
In order to test these findings in vivo, we used a 
previously described murine model of AML based on a 
xenograft flank tumor model using K562 cells. Treatment 
with HXR9 significantly reduced tumor growth compared 
to vehicle (PBS) alone or CXR9, and combining HXR9 
with the PKC inhibitor Ro31 resulted in a significantly 
longer delay in tumor growth (Figure 7).
DISCUSSION
The HOX genes have previously been shown to have 
a key role in the development of a malignant phenotype 
in AML, although this has principally been related to 
their incorporation in chimeric oncogenes formed by 
chromosomal breakage and rearrangement [1]. Less is 
known of their role in their wild type from, although the 
Figure 3: Annexin assay for detection of cell death in AML-derived cell lines. Cells were treated with the IC50, 2xIC50, or 
3xIC50 of HXR9, and with a concentration of CXR9 equivalent to the highest concentration of HXR9 for 2 hours. Cells were then stained 
with annexin V and 7-AAD and analysed by flow cytometry. The number of early apoptotic and dead cells increased with increasing HXR9 
concentrations. Results are expressed as the mean of 3 separate experiments and error bars show the SEM. *p < 0.05, **p < 0.01, ***p < 
0.001 and ****p < 0.0001 with respect to untreated cells.
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overexpression of a number of HOX genes is important 
for cell survival and drug resistance [3]. In this study, 
we examined the relationship between overall survival 
and the expression of individual HOX genes in AML. 
It was previously shown that high HOXA9 expression 
was associated with a poor outcome in this malignancy 
Figure 4: A. Inhibition of apoptosis by Ac-DEVD-CHO in AML K562 cells using Z-DEVD-R110. Cells were treated with IC50, 
2xIC50, 3xIC50 of HXR9, with an equivalent CXR9 to the highest concentration of HXR9 or untreated (control) for 2 hours. The cells were 
then lysed and the Z-DEVD-R110 substrate was added. The results were normalised to lysis buffer alone. There was no statistical difference 
in caspase-3 activity between both HXR9- or CXR9-treated cells and untreated control cells. Graphs show the mean of 3 independent 
experiments and error bars show the SEM. B. Nuclear staining of K562 cells either untreated or incubated for 2 hours with 10 µM HXR9. 
C. Analysis of transcriptional changes of several pro- and anti-apoptotic genes upon HXR9 treatment. K562 cells were treated with the IC50 
of HXR9, CXR9 or untreated (control) for 2 hours and gene expression was analysed using RT-PCR. There was no significant change in 
any of the analysed genes. Results are presented as a ratio with β-actin (x10 000). Statistical analysis was performed using student’s t-test 
by comparing the relative expression of a gene of interest in HXR9 or CXR9 treated cells to its counterpart in untreated cells. Graphs show 
the mean of 3 independent experiments and error bars show the SEM. D. The effect of ATP depletion on HXR9 cytotoxicity. Cells were 
pre-incubated with or without 40 mM fructose and then with a range of HXR9 concentrations (2.5 μM - 50 μM) for 2 hours prepared in 
media either with or without 40 mM fructose, red and blue curves, respectively. HXR9 cytotoxicity was then measured by assessing LDH 
enzyme activity in cell-free supernatants. ATP depletion did not inhibit HXR9-induced death. Graphs show the mean of 3 independent 
experiments and error bars show the SEM. E. General inhibition of caspase activity in HXR9 treated AML cell lines by z-VAD-FMK. Cells 
were pre-treated either with or without 50μM z-VAD-FMK for 1 hour, and then treated with the IC50, or 2xIC50 of HXR9 for 2 hours or 
with 17.5 μM DNR for 24 hours, which was used as a positive control. There was no statistical difference in terms of sensitivity to HXR9 
between pre-treated cells with or without 50μM z-VAD-FMK. Graphs show the mean of 3 independent experiments and error bars show the 
SEM. ****p < 0.0001 with respect to z-VAD-FMK untreated cells. F. and G. Effect of CsA on HXR9 cytotoxicity. Cells were pre-treated 
with or without 5μM CsA for 1 hour, and then with the IC50, 2xIC50, 3xIC50 of HXR9, 20 mM H2O2 (positive control), or were left untreated 
(negative control) for 2 hours with or without 5 μM CsA. The cells were then stained with annexin V and 7-AAD and analysed by flow 
cytometry. There was no statistical difference in the proportion of viable cells between K562 cells F. incubated with or without 5μM CsA, 
while incubation with 5μM CsA led to a significant decrease in proportion of viable HL-60 cells G.. Graphs show the mean of 3 independent 
experiments and error bars show the SEM. *p < 0.05, ***p < 0.001 and ****p < 0.0001 with respect to 5 μM CsA untreated cells.
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[2], although in the larger cohort examined here this 
relationship was only of borderline significance. The 
reason for this difference is unclear, although it may 
reflect the high level of functional redundancy amongst 
HOX genes with respect to proliferation and survival. 
Indeed, we found that the expression of a number of other 
HOX genes in AML showed a strong association with 
survival, including HOXA5, which has been shown to be 
upregulated by the H3K79 methyltransferase hDOT1L in 
MLL-AF10-mediated leukaemogenesis [19].
The strong relationships between the elevated 
expression of multiple HOX genes in AML and patient 
survival support the possibility that HOX proteins could 
be therapeutic targets in this malignancy, and this is 
supported further by our findings that inhibition of HOX/
PBX dimers cause cell death in AML-derived cell lines 
and primary AML cells. Taken together, our findings 
point to a mechanism of HXR9-mediated cell death that 
depends not on apoptosis, but instead on necroptosis, and 
which can be blocked by PKC signaling. Necroptosis 
is considered to be a regulated form of necrosis that in 
some respects parallels apoptosis, as it can be triggered 
by the same external stimuli [18]. It is a major mechanism 
of cell death in chronic lymphocytic leukaemia (CLL) 
[20], induced by drugs that target Bcl-2 [21] and the 
proteasome [22]. In addition, the induction of necroptosis 
in AML cells has been used as a strategy to overcome 
resistance to apoptosis, through the combined use of a 
Smac mimetic that inhibits XIAP and agents that promote 
DNA demthylation [23]. It has also been shown to mediate 
Figure 5: Evaluation of potential cell death pathways. A. Inhibition of RIP1 rescues HL-60 cells from HXR9-mediated cell 
killing. RIP1 was inhibited using 50 µM Nec1. Hydrogen peroxide was used as a positive control as it has previously been shown to induce 
RIP1-dependent cell killing. B. Cells were pre-treated with or without 25 μM of the p38 inhibitor SB302580 for 1 hour, and then with 
a titration of HXR9 prepared in media with or without 25 μM SB302580, red and blue curves, respectively. The cytotoxicity of HXR9 
was analysed by measuring LDH enzyme activity in cell-free supernatants. Pre- and co-treatment of cells with 25 μM SB302580 did not 
affect the cytotoxicity of HXR9. Statistical significance was tested using the student’s t-test. Graphs show the mean of 3 independent 
experiments and error bars show the SEM. C. Cells were pre-treated with or without 20 μM of the MEK/ERK inhibitor U0126 for 1 hour, 
and then with increasing concentrations of HXR9 prepared in media with or without 20 μM U0126, red and blue curves, respectively. The 
proportion of surviving cells was then measured using the LDH assay. Pre- and co-treatment of cells with 20μM U0126 did not prevent 
HXR9 cytotoxicity. Graphs show the mean of three independent experiments and error bars show the SEM. D. The effect of blocking p53 
protein on HXR9 cytotoxicity. Cells were pre-treated with or without 40 μM PFT-α for 1 hour, and then for 2 hours with a titration of HXR9 
prepared in media supplemented with or without 40 μM PFT-α, red and blue curves, respectively. Graphs show the mean of 3 independent 
experiments and error bars show the SEM. E. HXR9 treatment of K562 and HL-60 cells leads to a significant increase in expression of the 
p21 tumor suppressor gene. p21 expression was measured using quantitative PCR after 2 hours of incubation with the IC50 concentration 
of HXR9 for each cell type. F. p21 protein expression was measured using an ELISA with the same concentrations of HXR9.
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the killing of AML cells by a diphtheria toxin-GMCSF 
conjugate [24]. Despite this, the lack of any apoptosis 
following HXR9 treatment in these AML-derived cell 
lines is curious, as some solid malignancies have been 
shown to undergo apoptosis and can, for example, be 
rescued by the inhibition of caspase activity [8, 25]. 
PKC has not previously been show to directly 
interact with the necroptosis pathway, although signaling 
through PKC is known to promote the transcription of 
pro-survival genes, and to be a potential target in CLL 
[26]. Furthermore, the delta-PKC isotype was previously 
identified as a critical regulator of TNF signalling in 
adherent neutrophils. Delta PKC associates with tumour 
necrosis factor receptor-1 (TNFR-1) in response to 
TNF binding whereupon it promotes receptor serine 
phosphorylation and consequently enhances binding of 
TNFR-1-associated death domain protein (TRADD) 
to TNFR-1 and formation of a TNFR1-TRADD-RIP1 
complex [27]. The formation of this complex in turn 
results in the polyubiquitination of RIP1 and activation 
of NF-kB signalling, which promotes cell survival. 
Conversely, disruption of this complex leads to RIP 
deubiquitination, and its subsequent recruitment to a 
complex with either Caspase 8, leading to apoptosis, or 
its phosphorylation by RIP1 kinase followed by binding 
to RIP3 and the induction of necroptosis (Figure 8) [28]. 
Our findings indicate that the latter pathway is important 
as an inhibitor of RIP1 kinase, but not a global caspase 
inhibitor, significantly reduced the sensitivity of AML 
cells to killing by HXR9.
In addition to inhibiting necroptosis, our findings 
indicate that HOX/PBX dimers block p21 expression 
in AML cells at both the RNA and protein level. The 
relationship between p21 and apoptosis is complex and 
Figure 7: Inhibition of K562 tumor growth in a mouse xenograft model. Tumors were initiated by subcutaneous injection of 
K562 cells in to the flank of each mouse and were treated intratumourally with HXR9 or CXR9 at a dose of 50 mg/Kg, or Ro31 at a dose 
of 10 mg/Kg, or both HXR9 and Ro31, every 3 days. 
Figure 6: Inhibition of PKC sensitizes cells to killing by HXR9. PKC was inhibited using Ro31-8220, reducing the IC50 of 
HXR9 to 5 µM for K562 cells, and to 10.7 µM for HL-60 cells.
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varies between cell types: p21 can promote apoptosis in 
some contexts but prevent apoptosis in others [29]. The 
lack of apoptosis after HXR9 treatment might be a result 
of increased p21 expression (Figure 8), although further 
dissection of this complex molecular pathway is needed 
in order to confirm this.
The synergistic interaction between HXR9 and 
PKC-mediated signaling is particularly noteworthy, as 
it points to possible combinatorial approaches when 
targeting AML using HOX/PBX inhibitors, and indeed this 
was supported by results obtained using a murine model. 
Furthermore, the strong relationship between survival 
in AML and the expression of a number of HOX genes 
indicates that targeting HOX function via the disruption 
of HOX/PBX dimers could be a useful therapeutic target 
in this disease, and that HOX gene expression might 
also allow patients to be stratified according to their 
likely response to such a treatment. We hope that further 
work will help us to refine this approach to establish the 
selective activation of necroptosis as a therapeutic target 
in AML.
MATERIALS AND METHODS
Analysis of AML microarray data
The bioinformaritcs analysis was performed in R. 
The GSE23312 microarray data set [30] was downloaded 
from the GEO database [11] and pre-processed in R/
Bioconductor [31]. The patients were stratified equally 
into 2 groups based on the expression levels of each HOX 
gene. The association between the expression level and 
Figure 8: Activation of RIP1-mediated necroptosis. TNF-α binding to TNFR1 can activate NF-κB activation, apoptosis, 
or necroptosis. Phosphorylation of TNFR1 favours TRADD recruitment that in turn leads to RIP1 ubiquitination (complex I), and the 
subsequent activation of the NF-κB pathway via NEMO. Inhibition of PKC delta leads to the deubiquitination of RIP1 and the formation 
of either complex IIa with FADD and caspase-8, or, if RIP1 is phosphorylated, the formation of a necrosome with phosphorylated RIP3 
(complex IIb), leading to necroptosis. A dimer between HOX and PBX proteins represses the necroptosis pathway, possibly through 
inhibition of RIP kinase. HOX/PBX dimers also repress p21 expression, which might in turn block apoptosis (dotted line). Abbreviations: 
PKC, protein kinase C; NEMO, NF-kappa-B essential modulator; RIP1, Receptor-interacting protein 1; cIAP2, Cellular inhibitor of 
apoptosis-1; TRAF, TNF receptor associated factors; FADD, Fas-associated protein with death domain; TRADD, Tumor necrosis factor 
receptor type 1-associated death domain protein.
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patient survival was assessed using Kaplan-Meier plots in 
R using the survival package.
Primary AML cell isolation
Primary AML cells were obtained after patient’s 
informed consent and approval of the study by the ethics 
committee (SGUL). Cells were isolated from bone marrow 
or peripheral blood using density gradient centrifugation 
and cultured in IMDM medium (Life Technologies, 
Carlsbad, CA, USA) with 10% foetal bovine serum 
(FBS; Biochrom GmbH, Berlin, Germany), 10% horse 
serum (HS; Gibco, Invitrogen, Carlsbad, USA), and 1 µM 
hydrocortisone (Sigma-Aldrich, St. Louis, MO).
Proliferation assays
For adaptation to oxygen content, primary AML 
cells were cultured for three days under hypoxic conditions 
and then seeded for proliferation assays. The cells were 
subsequently incubated with different concentrations 
of HXR9 or CXR9 ranging from 100 nM to 5000 nM. 
All assays were done in triplicate. Cell numbers were 
determined on day 3 after HXR9/CXR9 treatment using 
the cell viability analyzer Vi-Cell XR (Beckman Coulter, 
Brea, CA, USA). Each assay was performed at least twice.
P21 ELISA
P21 protein was measured using the p21 simplestep 
ELISA kit (Abcam, Cambridge, UK) according to the 
manufacturer’s instructions.
AML derived cell lines
In this study we used three primary AML cell lines 
derived from patients with de novo mutations: KG-1, a cell 
line derived from an erythroleukaemia [32], HEL 92.1.7, 
an erythroleukaemia cell line [33], and HL-60, a cell line 
obtained from acute promyelocytic leukaemia (APML) 
[34]. The two other lines, K562 (26) and KU812F (27) 
were derived from secondary AML (chronic myeloid 
leukaemia cells in blast crisis).
HXR9 and CXR9 synthesis
The synthesis of these peptides has been described 
previously [35].
Tissue culture
K562, KU812F and HEL92.1.7 cells were grown in 
RPMI-1640 medium complemented with 10% FBS, 5% 
L-glutamine and 5% antibiotics (1000 units of penicillin/
ml and 10 mg/ml streptomycin, P/S). KG-1 and HL-60 
cells were cultured in IMDM supplemented with 20% 
FBS and 5% antibiotics. All cell lines were cultured in 
T-75 sterile cell culture flasks at 37°C in a humidified 
environment containing 5% CO2 and 95% air. 
Gene expression analysis by RT-PCR
Gene expression analysis using SYBR greenTM was 
carried out in order to measure the changes in expression 
of genes of interest. The primer sequences for the pro- and 
anti-apoptotic genes are listed in Table 1. Each gene of 
interest was tested in triplicate. The housekeeping gene 
β-actin was used as an endogenous control. The thermal 
profiles employed were: heating once for 10 minutes at 
95°C, followed by 30 seconds at 95°C, 1 minute at 60°C, 
30 seconds at 72°C for 40 cycles. The mean of the cycle 
threshold values of the triplicate repeats for each gene was 
calculated and used for measuring gene expression. 
Lactate dehydrogenase (LDH) assay
Cells were suspended in 5% FBS of the appropriate 
culture medium at a concentration of 5×105 cell/ml and 
seeded in 96-well flat-bottom plates at a concentration of 
5×104 cell/well. The cells were then treated with 100 μl 
of a serial dilution of HXR9 or its negative control CXR9 
in 5% FBS for 2 hours. Each plate included untreated 
cells (negative control), 2% triton-treated cells (positive 
control), and 5% FBS medium only (background control). 
LDH enzymatic activity was determined according to the 
manufacturer’s instructions.
Annexin V- PE assay
The annexin V-PE assay was used to quantify 
the percentage of the apoptotic cells and evaluate the 
mechanism of cell death. Cells were suspended in 5% 
FBS of the appropriate culture medium at a concentration 
of 1×106 cell/ml and seeded in 96-well flat-bottom plates 
at a concentration of 1×105 cell/well. The percentage of 
the different cell populations, viable, early apoptotic and 
dead cells, were plotted by GraphPad Prism software 
(California, USA) on column graphs to allow the 
comparison of treated and untreated negative control 
cells. Each experiment was repeated at least 3 times 
independently. 
DAPI staining
Cells were suspended in 5% FBS culture medium 
at a concentration of 1×106 cell/ml and seeded in 24-well 
plates at a concentration of 5×105 cell/well. Then cells 
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were treated either with HXR9 at the IC50 or double the 
IC50, in duplicate. Each plate included untreated negative 
control cells. 
Cyclosporin A (CsA) protection assay
CsA attenuates mitochondrial permeability transition 
pore (mPTP) formation by binding to cyclophilin D 
(cypD), which is required for mPTP formation in necrotic 
mitochondrial cell death [36-38]. In this assay cells 
were pre- and co-treated with or without 5 μM CsA and 
hydrogen peroxide (H2O2) treatment was used as a positive 
control. Cells were treated in triplicate with HXR9 at the 
IC50, double or triple the IC50 or with 20 mM H2O2. Cell 
pellets were prepared and stained with annexinV-PE as 
described for the annexinV-PE assay. The proportion 
of positively stained cells was determined using flow 
cytometry. 
Necrostatin-1 (Nec-1) protection assay
Nec-1 is a selective inhibitor of receptor interacting 
protein 1 (RIP1) [39]. RIP1 inhibition prevents a form of 
programmed necrosis called necroptosis [40]. Cells were 
pre- and co-treated with 50 μM Nec-1 using the same 
method described above for the CsA protection assay.
Fructose protection assay
Fructose is a glycolytic substrate that at high 
concentrations significantly sequesters phosphate and 
accordingly intracellular ATP is depleted. This selective 
depletion of ATP protects cells from apoptosis, but leaves 
sufficient ATP to rescue cells from spontaneous necrosis 
[41]. Cells were treated with HXR9 or with 2% triton as a 
positive control and cell viability was measured using the 
LDH assay as described above. 
Ethilenediaminetetra-acetic acid (EDTA) and 
HXR9 cytotoxicity
The role of Ca2+ in HXR9-mediated cell death was 
assessed by two different assays, LDH and annexin V, as 
described for the fructose protection and CsA protection 
assays, respectively. 
Inhibition of mitogen activated protein kinase 
(MAPK) pathways
The effect of HXR9 on MAPK pathways was 
studied using specific inhibitors of extracellular signal-
regulated kinase (ERK), Jun N-terminal kinase (JNK), and 
p38 [42], which were U0126 monoethanolate, SP600125, 
and SB203580, respectively. Experiments were performed 
as described for the fructose protection assay. 
NADPH oxidase (NOX) inhibition
NOX is a generator of intracellular reactive oxygen 
species (ROS) [43]. The effects of NOX on the efficiency 
of HXR9 were assessed using the NOX inhibitor 
diphenyleneiodonium chloride (DPI) [44]. Cells were pre- 
and co-treated with or without 60 μM DPI. The assessment 
of DPI effect on the cytotoxicity of HXR9 was performed 
Table 1: Pro- and anti-apoptotic and β-actin gene primers used for PCR amplification
Gene Forward Sequence 5’-3’ Reverse Sequence 5’-3’ Amplicon Length (bp)
Bad CGGAGGATGAGTGACGAGTT GATGTGGAGCGAAGGTCACT 180
Bak1 TTTTCCGCAGCTACGTTTTT GGTGGCAATCTTGGTGAAGT 248
Bax TTTGCTTCAGGGTTTCATCC CAGTTGAAGTTGCCGTCAGE 246
Bcl2 GAGGATTGTGGCCTTCTTTG ACAGTTCCACAAAGGCATCC 170
Bid CTGCAGGCCTACCCTAGAGA ACTGTCCGTTCAGTCCATCC 195
XIAP GGGGTTCAGTTTCAAGGACA CGCCTTAGCTGCTCTTCAGT 182
Apaf1 TTCTGATGCTTCGCAAACAC CTGGCAAATCTGCCTTCTTC 237
Caspase-3 TTTTTCAGAGGGGATCGTTG CGGCCTCCACTGGTATTTTA 151
Caspase-6 ATCCTCACCGGGAAACTGTG AATTGCACTTGGGTCTTTGC 161
Caspase-7 AGTGACAGGTATGGGCGTTC CGGCATTTGTATGGTCCTCT 164
Caspase-9 CTAGTTTGCCCACACCCAGT GCATTAGCGACCCTAAGCAG 172
PARP1 GCTCCTGAACAATGCAGACA CATTGTGTGTGGTTGCATGA 233
c-FOS CCAACCTGCTGAAGGAGAAG GCTGCTGATGCTCTTGACAG 232
p21 GACACCACTGGAGGGTGACT CAGGTCCACATGGTCTTCCT 171
p53 GTGGAAGGAAATTTGCGTG CCAGTGTGATGATGGTGAGG 183
β-actin ATGTACCCTGGCATTGCCGAC GACTCGTCATACTCCTGCTTG 227
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as described for the fructose protection assay. 
μ-calpain inhibition
Calpains are Ca2+-dependent cysteine proteases 
that commonly activated in Ca2+ dependent cell death 
mechanisms [45]. Among them, μ-calpain is one of the 
most extensively studied in apoptosis/necrosis processes. 
Calpain inhibitor I (N- Acetyl- Leu- Leu- Norleu- al) 
was used to inhibit the Ca2+/μ-calpain pathway. Cells 
were pre- and co-treated with or without 60 μM calpain 
inhibitor I. The assessment of the role of μ-calpain in the 
cytotoxicity of HXR9 was performed as described for the 
fructose protection assay.
PKC inhibition
Ro31-8220 (methanesulfonate salt) was used to 
inhibit and assess the role of PKC in HXR9 cytotoxicity. 
Cells were pre- and co-treated with or without 30 μM 
Ro31-8220, and its effects on the cytotoxicity of HXR9 
was assessed as for the fructose protection assay.
Heme oxygenase-1 (HO-1) inhibition
HO-1 is an anti-apoptotic protein [46]. 
Protoporphyrin IX (PPIX) was used to inhibit HO-1 
protein and assess its role in the cytotoxicity of HXR9. 
Cells were pre- and co-treated with or without 50 μM 
of PPIX, and the effect of HO-1 inhibition on HXR9 
cytotoxicity was determined as described for the fructose 
protection assay.
p53 inhibition
Pifithrin-α (PFT-α) is an inhibitor of p53-dependent 
apoptosis and was used to block and assess the role of 
p53 in the cytotoxicity of HXR9. Cells were pre- and co-
treated with or without 40 μM of PFT-α, and the role of 
p53 in HXR9 cytotoxicity was assessed as described for 
the fructose protection assay.
In vivo model
Female C57BL/6, nude and severe combined 
immune-deficient mice, approximately 6 to 8 weeks old, 
were purchased from Jackson laboratory, Kent, UK. These 
mice were maintained in pathogen-free cages and fed 
with irradiated food and acidified water. All experiments 
were performed under the compliance of Home Office 
and institutional instructions. The mice were anesthetised 
using isoflurane and K562 cells (5x106 cell/mouse) were 
then injected subcutaneously into the flank. Flank tumour 
sizes were measured three times a week using calliper 
measurement. Tumour sizes were calculated using the 
formula: (length x width x width)/2. When the flank 
tumour became palpable, the mice were divided into two 
groups with one treated intratumourly with 50 μl of the 
indicated dose of HXR9, CXR9, Ro31, HXR9 combined 
with HXR9, or with PBS alone (control group). Mice were 
sacrificed if the tumour volume was ≥ 1500 mm3. 
Statistical analysis
Calcusyn software was used to determine the IC50 
of the different drugs for the different cell lines and for 
assessing whether the interaction between HXR9 with 
DNR or MTX was synergistic, additive or antagonistic, 
as described below. Student’s t-test was applied for data 
analysis of all assays using GraPhpad Prism software. 
Results are expressed as the mean of 3 separate 
experiments with error bars to show the SEM. Statistical 
significance was determined by comparing the different 
conditions in each assay with each other and considered 
significant when p < 0.05 (*), p < 0.01 (**), p < 0.001 
(***), or p < 0.0001 (****). The IC50 of HXR9, DNR, 
and MTX for different cell lines were calculated by the 
median-effect equation of Chou [47] using Calcusyn 
software (Biosoft, Cambridge, UK). The combination 
effects of HXR9 with either DNR or MTX were calculated 
using the combination index (CI) equation [48] with 
Calcusyn Software. CI > 1, CI = 1, and CI < 1 indicate 
antagonism, an additive effect and synergism, respectively. 
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